Overview

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
0
Participant gender:
All
Summary
The aim of the present study is to compare the efficacy of liraglutide vs. naltrexone/bupropion on metabolic and cardiovascular risk markers, weight loss, as well as the postprandial secretion of gastrointestinal hormones involved in hunger and satiety, after a test meal. The study will include 40 patients, who will further be divided into two treatment groups (20 patients on liraglutide vs. 20 patients on naltrexone/bupropion). The patients will be examined at baseline, 3 and 6 months after the treatment initiation.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
National and Kapodistrian University of Athens
Collaborator:
Athens Medical Center
Treatments:
Bupropion
Liraglutide
Naltrexone
Criteria
Inclusion Criteria:

- Age ≥18 years with BMI ≥ 30 kg / m2 or BMI ≥ 27 kg / m2 in the presence of
dyslipidemia or hypertension or obstructive sleep apnea or fatty infiltration or
prediabetes.

Exclusion Criteria:

1. Presence of any clinical contraindications for the administration of liraglutide or
bupropion / naltrexone

2. Bariatric surgery

3. Diabetes type 2

4. Active malignancy

5. Medication that affects weight (eg corticosteroids, phenothiazines)